Year All202620252024202320222021202020192018201720162014201320112010 June 1, 2018 Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference May 14, 2018 Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results May 9, 2018 Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity May 9, 2018 Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference April 2, 2018 Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome March 19, 2018 Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018 March 12, 2018 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results March 7, 2018 Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March January 4, 2018 Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity November 14, 2017 Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
May 9, 2018 Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
May 9, 2018 Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
April 2, 2018 Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
March 19, 2018 Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
January 4, 2018 Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
